Article Data

  • Views 557
  • Dowloads 145

Original Research

Open Access

Surgical management and outcomes of metastatic tumors to the ovaries

  • S. Rahatli1,*,
  • H. Akilli2
  • N. Haberal3
  • O. Altundag1
  • A. Haberal2
  • A. Ayhan2

1Deptartment of Medical Oncology, Faculty of Medicine, Baskent University, Ankara, Turkey

2Deptartment of Obstetrics and Gynecology, Faculty of Medicine, Baskent University, Ankara, Turkey

3Deptartment of Pathology, Faculty of Medicine, Baskent University, Ankara, Turkey

DOI: 10.12892/ejgo4821.2019 Vol.40,Issue 5,October 2019 pp.820-824

Accepted: 30 July 2018

Published: 10 October 2019

*Corresponding Author(s): S. Rahatli E-mail: samedrahatli@hotmail.com

Abstract

Purpose of Investigation: Gynecologic and non-gynecologic tumors occasionally metastasize to the ovaries. Aim of this study was to describe the clinicopathologic characteristics and survival outcomes of patients with metastatic tumors to the ovaries. Materials and Methods: Between 2007-2017, 859 operations were performed in this center with initial diagnosis of ovarian mass. Seventy-five patients who had metastatic tumor to the ovaries in pathological examination were included the study. Results: Median overall survival of all patients was 26 ± 5.9 months, three-year survival was 62%, and five-year survival was 37%. Patients who developed metachronous metastasis had better survival than patients who had synchronous metastasis (p = 0.05). Bilateral ovarian involvement was related with poor survival compared with unilateral involvement. Chemotherapy had beneficial effect on overall survival. Median survival in extensive surgery group was 30.9 months and it was better than minimal surgery group with 15.6 months, however it was not statistically significant (p = 0.973). Conclusion: The prognosis of the metastatic tumors to the ovaries is poor but achieving a complete resection and optimal debulking surgery may improve survival in some histologic subgroups.

Keywords

Ovarian metastasis; Krukenberg tumors; Non-genital cancers; Chemotherapy; Cytoreductive surgery

Cite and Share

S. Rahatli,H. Akilli,N. Haberal,O. Altundag,A. Haberal,A. Ayhan. Surgical management and outcomes of metastatic tumors to the ovaries. European Journal of Gynaecological Oncology. 2019. 40(5);820-824.

References

[1] Waal de Y.R., Thomas C.M., Oei A.L., Sweep F.C., Massuger L.F.: “Secondary ovarian malignancies: frequency, origin, and characteristics”. Int. J. Gynecol. Cancer, 2009, 19, 1160.

[2] Skírnisdóttir I., Gramo H., Holmberg L.: “Non-genital tract metastases to the ovaries presented as ovarian tumors in Sweden 1990- 2003: occurrence, origin and survival compared to ovarian cancer”. Gynecol. Oncol., 2007, 105, 166.

[3] Petru E., Pickel H., Heydarfadai M., Lahousen M., Haas J., Schaider H., et al.: “Nongenital cancers metastatic to the ovary”. Gynecol. Oncol., 1992, 44, 83.

[4] Kim W.Y., Kim T.J., Kim S.E., Lee J.W., Lee J.H., Kim B.G.: “The role of cytoreductive surgery for non-genital tract metastatic tumors to the ovaries”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2010, 149, 97.

[5] Jeung Y.J., Ok H.J., Kim W.G., Kim S.H., Lee T.H.: “Krukenberg tumors of gastric origin versus colorectal origin”. Obstet. Gynecol. Sci., 2015, 58, 32.

[6] Kubeček O., Laco J, Špaček J., Petera J., Kopecký J, Kubečková A., et al.: “The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive review”. Clin. Exp. Metastasis, 2017,34, 295.

[7] Shah B., Tang W., Karn S.: “An Up-to-Date Understanding of the “Krukenberg Tumor” Mechanism”. Adv. Reprod. Sci., 2016, 4, 31.

[8] Wu F., Zhao X., Mi B., Feng L.U., Yuan N.A., Lei F., et al.: “Clinical characteristics and prognostic analysis of Krukenberg tumor”, Mol. Clin. Oncol., 2015, 3, 1323.

[9] Ayhan A, Guvenal T, Salman M.C., Ozyuncu O., Sakinci M, Basaran M.: “The role of cytoreductive surgery in nongenital cancers metastatic to the ovaries”. Gynecol. Oncol., 2005, 98, 235.

[10] Brigand C., Monneuse O, Mohamed F., Sayag-Beaujard A.C., Isaac S., Gilly F.N., et al: “Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study”. Ann. Surg. Oncol., 2006, 13, 405.

[11] Jeung Y.J., Ok H.J., Kim W.G., Kim S.H., Lee T.H.: “Krukenberg tumors of gastric origin versus colorectal origin”. Obstet. Gynecol. Sci., 2015, 58, 32.

[12] Fianza A.. La, Alberici E.., Pistorio A., Generoso P.: “Differential diagnosis of Krukenberg tumors using multivariate analysis”. Tumori, 2002, 88, 284.

[13] Moore R.G., Chung M, Graini C.O., Gajewski W., Steinhoff M.M.: “Incidence of metastasis to the ovaries from nongenital tract primary tumors”. Gynecol. Oncol., 2004, 93, 87.

[14] Saltz L.B., Clarke S., Díaz-Rubio E., Scheithauer W., Figer A., Wong R., et al.: “Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study”. J. Clin. Oncol., 2008, 26, 2013.

[15] Stintzing S., Modest D.P., Rossius L., Lerch M.M., von Weikersthal L.F., Decker T., et al.: “FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial”. Lancet Oncol., 2016, 17, 1426.

[16] Ganesh K., Shah R.H., Vakiani E., Nash G.M., Skottowe H.P., Yaeger R., et al.: “Clinical and genetic determinants of ovarian metastases from colorectal cancer”. Cancer, 2017, 123, 1134.

[17] Bigore V., Morice P., Duvillard P, Antoine M., Cortez A, Flejou J.F., et al.: “Ovarian Metastases From Breast Cancer Report of 29 Cases”. Cancer, 2010, 116, 799.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top